DIA's Annual Canadian Meeting: New Reality / New Frontiers
Oct 29 2013 7:00AM - Oct 30 2013 3:00PM | Ottawa Marriott
100 Kent Street
Ottawa, ON K1P5R7
CANADA
Overview
Tutorials: October 28, 2013
Meeting: October 29-30, 2013
New Reality/New Frontiers
Today’s patient reality is driving change in drug development and regulations. Drug companies are exploring new technologies bringing to the forefront modern novel products revolutionizing the global and local approach to medicine. Widespread advancements in areas of personalized medicines and cell therapies, promising patient benefits, are being studied. Additionally, a number of blockbuster drugs’ patents are expiring allowing for the introduction of generic drugs and subsequent entry biologics. This places an increased importance on driving pipelines forward in an efficient manner taking into consideration the ever changing regulatory environment. This has driven innovative development that can address critical disease areas, and will ultimately maximize benefits to patients. In line with New Realities, Heath Canada continues to modernize activities including a new pathway for initiatives such as the authorization of drugs for rare diseases. There is recognition of the need to provide the patient and the health care professionals with increased accessibility to drug information and comprehensive drug labels. This meeting will explore how patients, health care professionals, industry and the regulator continue to evolve and liaise. All the while embracing changes to drug development and regulatory requirements, and encouraging global collaborations and transparency placing upfront patient safety and greater access to efficacious drugs.
BENEFITS:
- Leave with solutions for development strategy.
- Network with colleagues and stakeholders to discuss new ideas.
- Look at a particular operations topic from different angles.
- Interact with speakers representing patients, industry and regulatory agencies.
- Enhance awareness of scientific areas.
- Learn the latest regulatory initiatives.
Featured Topics
- International Regulatory Harmonization
- Electronic Gateway
- Aligning / Harmonizing in the Post-market Domain
- Social Media
- Research Networks and Translation Medicine
- ICH / Quality
- Clinical Trial Disclosure
- Crisis Management
- New Business Modules
- Advertising Guidelines
- Regulatory Modernization
Who Should Attend
This program will benefit individuals involved in:
- Regulatory Affairs
- Policy/Pharmacoeconomics
- Clinical Development
- Drug Safety/Pharmacovigilance
- Patient Safety
- Medical Communications
- Quality Operations
Learning Objectives
At the conclusion of this meeting, participants should be able to:
- Describe the current regulatory environment.
- Recognize the challenges faced by the industry and regulators in drug development, market access and regulation in Canada.
- Identify new ways of thinking about worldwide advancements in patient benefits and implementing them for Canada.
- Discuss the evolution of drug development and regulatory requirements while encouraging global collaboration.
- Explain the need to provide patient and health care professionals with increased accessibility to drug information in order to make informed decisions.
Special Offers
Group Discounts Available! Register 3 and Get the 4th FREE!
Hotel & Travel
A limited number of rooms are available at the reduced rate shown below (DIA rate is guaranteed until September 25, 2013, or until room block is filled). Attendees can follow this link to make their hotel reservations, or by calling +1.212.532.1660 or in the USA at 1.800.221.3531. When making your hotel reservation by phone, please select option 1 for “Hotel Reservations,” inform the phone agent that it is a DIA event, and provide them with the date and title of the meeting.
Please Note: In order to receive the reduced room rate, hotel reservations must be made as noted above and not directly with the hotel.
Standard Room Rate $153 CN
Hotel Address: 100 Kent Street, Ottawa, ON K1P 5R7
The most convenient airport is Ottawa International Airport and attendees should make both airline and hotel reservations as early as possible.
Contact Information
Exhibits
The Annual Canadian Meeting offers interested companies the opportunity to exhibit with a tabletop display.
Tabletop Fee: $1,500
Fee Includes:
- One six-foot skirted table
- One chair
- Standard electricity
Each tabletop rental requires at least one registered attendee to staff the table. All tabletop staff must be registered conference attendees.
Tabletop Exhibit Dates:
October 29-30, 2013
Useful Links
Registration Fees
Member
- Charitable Nonprofit/Academia Member
- $745.00
- Member Government
- $595.00
- Member Standard
- $1340.00
- Member Standard (As of 10/08/2013)
- $1490.00
Non-Member
- Charitable Nonprofit/Academia Nonmember
- $920.00
- NonMember Standard
- $1665.00
- NonMember Government
- $770.00
Group Discounts
Register three individuals from the same company and receive complimentary registration for a fourth! All four individuals must register and prepay at the same time – no exceptions. To take advantage of this offer, click on “View PDF” below and make four copies of the registration form. Complete the main registration for each of the four registrants and include the names of all other group registrants in the Group Discount section. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.
Register Online
Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.